Achmea Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-9,333
| Closed | -$1.03M | – | 361 |
|
|
2025
Q1 | $1.03M | Hold |
9,333
| – | – | 0.02% | 326 |
|
|
2024
Q4 | $1.27M | Buy |
9,333
+971
| +12% | +$133K | 0.02% | 328 |
|
|
2024
Q3 | $963K | Buy |
8,362
+5,219
| +166% | +$601K | 0.02% | 365 |
|
|
2024
Q2 | $433K | Buy |
3,143
+754
| +32% | +$104K | 0.01% | 394 |
|
|
2024
Q1 | $329K | Sell |
2,389
-4,299
| -64% | -$592K | 0.01% | 418 |
|
|
2023
Q4 | $882K | Sell |
6,688
-2,967
| -31% | -$391K | 0.02% | 400 |
|
|
2023
Q3 | $1.09M | Sell |
9,655
-199
| -2% | -$22.4K | 0.02% | 382 |
|
|
2023
Q2 | $930K | Sell |
9,854
-213
| -2% | -$20.1K | 0.02% | 436 |
|
|
2023
Q1 | $1.02M | Buy |
10,067
+1,619
| +19% | +$164K | 0.03% | 391 |
|
|
2022
Q4 | $945K | Buy |
8,448
+2,710
| +47% | +$303K | 0.03% | 406 |
|
|
2022
Q3 | $609K | Buy |
5,738
+5,539
| +2,783% | +$588K | 0.02% | 458 |
|
|
2022
Q2 | $20K | Hold |
199
| – | – | ﹤0.01% | 597 |
|
|
2022
Q1 | $19K | Buy |
+199
| New | +$19K | ﹤0.01% | 620 |
|
|
2021
Q4 | – | Sell |
-199
| Closed | -$19K | – | 458 |
|
|
2021
Q3 | $19K | Buy |
+199
| New | +$19K | ﹤0.01% | 606 |
|